Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas
Glioma is a type of tumor occurring in the central nervous system. In recent decades, specific gene mutations and molecular aberrations have been used to conduct the glioma classification and clinical decisions. Siglec10 is a member of the sialic acid-binding immunoglobulin superfamily. In this stud...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.873655/full |
| _version_ | 1811312499764494336 |
|---|---|
| author | Hesong Wang Yanyan Feng Yuxiang Zhang Ting Wang Heng Xu Yuxing Zhi Yuyin Feng Lichun Tian Kai Yuan |
| author_facet | Hesong Wang Yanyan Feng Yuxiang Zhang Ting Wang Heng Xu Yuxing Zhi Yuyin Feng Lichun Tian Kai Yuan |
| author_sort | Hesong Wang |
| collection | DOAJ |
| description | Glioma is a type of tumor occurring in the central nervous system. In recent decades, specific gene mutations and molecular aberrations have been used to conduct the glioma classification and clinical decisions. Siglec10 is a member of the sialic acid-binding immunoglobulin superfamily. In this study, we investigated the expression and functions of siglec10 in gliomas. We analyzed the siglec10 expression in glioma patients with immunohistochemical (IHC) staining and evaluated the survival prognosis. The high siglec10 expression had a shorter survival prognosis than the low siglec10 expression in patients, especially in malignant gliomas. Bioinformatic datasets, including TCGA and CGGA, validated the IHC results and discovered the expression of siglec10 was higher in the malignant subtype than a benign subtype of gliomas. So, siglec10 is associated with the poor prognosis of gliomas. Furthermore, the related mechanisms of siglec10 in gliomas were investigated by functional enrichment analysis, including GSEA, GO, and KEGG analysis. Siglec10 was correlated with inflammatory mediators, inflammatory cells, and inflammatory pathways in gliomas. Siglec10 might take part in the immune response in the tumor microenvironment to induce glioma’s progression and metastasis. This study showed siglec10 was a biomarker in glioma, and it might be the potential target of glioma immunotherapy in the future. |
| first_indexed | 2024-04-13T10:37:15Z |
| format | Article |
| id | doaj.art-93b01597e9734e9ba58e0d4bd223bd22 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T10:37:15Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-93b01597e9734e9ba58e0d4bd223bd222022-12-22T02:50:01ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-11-011310.3389/fgene.2022.873655873655Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomasHesong Wang0Yanyan Feng1Yuxiang Zhang2Ting Wang3Heng Xu4Yuxing Zhi5Yuyin Feng6Lichun Tian7Kai Yuan8School of Life Sciences, Beijing University of Chinese Medicine, Beijing, ChinaShenzhen Bao’an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, ChinaDepartment of Neurosurgery, Sanbo Brain Hospital Capital Medical University, Beijing, ChinaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, ChinaQi-Huang Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, ChinaBeijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, ChinaGlioma is a type of tumor occurring in the central nervous system. In recent decades, specific gene mutations and molecular aberrations have been used to conduct the glioma classification and clinical decisions. Siglec10 is a member of the sialic acid-binding immunoglobulin superfamily. In this study, we investigated the expression and functions of siglec10 in gliomas. We analyzed the siglec10 expression in glioma patients with immunohistochemical (IHC) staining and evaluated the survival prognosis. The high siglec10 expression had a shorter survival prognosis than the low siglec10 expression in patients, especially in malignant gliomas. Bioinformatic datasets, including TCGA and CGGA, validated the IHC results and discovered the expression of siglec10 was higher in the malignant subtype than a benign subtype of gliomas. So, siglec10 is associated with the poor prognosis of gliomas. Furthermore, the related mechanisms of siglec10 in gliomas were investigated by functional enrichment analysis, including GSEA, GO, and KEGG analysis. Siglec10 was correlated with inflammatory mediators, inflammatory cells, and inflammatory pathways in gliomas. Siglec10 might take part in the immune response in the tumor microenvironment to induce glioma’s progression and metastasis. This study showed siglec10 was a biomarker in glioma, and it might be the potential target of glioma immunotherapy in the future.https://www.frontiersin.org/articles/10.3389/fgene.2022.873655/fullSiglec10prognosisgliomamechanismbiomarker |
| spellingShingle | Hesong Wang Yanyan Feng Yuxiang Zhang Ting Wang Heng Xu Yuxing Zhi Yuyin Feng Lichun Tian Kai Yuan Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas Frontiers in Genetics Siglec10 prognosis glioma mechanism biomarker |
| title | Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas |
| title_full | Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas |
| title_fullStr | Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas |
| title_full_unstemmed | Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas |
| title_short | Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas |
| title_sort | siglec10 an immunosuppressor and negative predictor of survival prognosis in gliomas |
| topic | Siglec10 prognosis glioma mechanism biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.873655/full |
| work_keys_str_mv | AT hesongwang siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT yanyanfeng siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT yuxiangzhang siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT tingwang siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT hengxu siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT yuxingzhi siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT yuyinfeng siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT lichuntian siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas AT kaiyuan siglec10animmunosuppressorandnegativepredictorofsurvivalprognosisingliomas |